Group 1 - The company will hold its third extraordinary general meeting of shareholders on December 25, 2025, as approved by the board of directors [1][88] - The meeting will combine on-site voting and online voting, with specific time slots for each [2][3] - All shareholders registered by the cut-off date of December 18, 2025, are entitled to attend and vote, including the option for proxy voting [4][5] Group 2 - The company plans to use up to RMB 300 million of idle funds for entrusted wealth management, with a term of 12 months from the approval date by the shareholders' meeting [22][23][31] - The investment will focus on high-credit, low-risk financial instruments, such as structured deposits and large-denomination certificates of deposit [22][26] - The board has authorized the chairman to make investment decisions within the approved limits [29][31] Group 3 - The company intends to conduct foreign exchange hedging to mitigate currency risk, with a maximum amount of USD 10 million or equivalent in other currencies [44][46][61] - The hedging activities will include various instruments such as forward foreign exchange contracts and interest rate swaps [48][56] - The board has approved the hedging plan, which will be implemented by the finance department under the chairman's authorization [53][61] Group 4 - The company will apply for a comprehensive credit limit of up to RMB 100 million from banks to support its business development and financing needs [67][68] - The credit facilities will include various types of financing, such as working capital loans and bank guarantees [68] - The board has authorized the chairman to handle all necessary procedures related to the credit application [69]

（编辑 任世碧） 证券日报网讯 12月9日晚间，英华特发布公告称，公司于2025年12月9日召开第二届董事会第二十次会 议，审议通过了《关于使用闲置自有资金进行委托理财的议案》，同意公司在确保资金安全且不会对公 司日常生产经营产生影响的前提下，使用额度不超过人民币30，000万元（含本数）的闲置自有资金进 行委托理财，投资期限自公司股东会审议通过之日起12个月，在上述额度和期限范围内，资金可循环滚 动使用。 ...

证券日报网讯 12月9日晚间，东亚药业发布公告称，公司于2025年12月9日召开了第四届董事会第十二 次会议及第四届监事会第十一次会议，分别审议通过了《关于使用暂时闲置的自有资金进行委托理财的 议案》。同意公司及子公司使用最高不超过人民币2.5亿元（含本数）的闲置自有资金进行委托理财， 使用期限自第四届董事会第十二次会议审议通过之日起一年内有效。在前述额度及期限范围内，各投资 主体可以循环滚动使用。本次委托理财事项无需提交公司股东大会审议。 （编辑 任世碧） ...

Core Viewpoint - The company announced its expected daily related transactions for the year 2026, stating that these transactions will not adversely affect its financial status or operational results, and will not harm the interests of shareholders, particularly minority and non-related shareholders [2][22]. Summary by Sections Daily Related Transactions Overview - The company held a board meeting on December 4, 2025, where the expected daily related transactions for 2026 were approved unanimously by the independent directors and the board [3][4][28]. - The expected transaction amounts do not meet the threshold for requiring shareholder meeting approval [4]. Related Parties and Relationships - **Mingpai Jewelry Co., Ltd.**: This company is controlled by individuals who hold over 5% of the company's shares and has a long-standing business relationship with the company [6][7]. - **Zhang Yiyuan Tea Co., Ltd.**: This company is also a related party due to its management being associated with the company's major shareholder [9][11]. - **Financial Street Capital Operation Group Co., Ltd.**: This entity is the indirect controlling shareholder of the company and is involved in various related transactions [11][12]. Transaction Details and Pricing Policies - The company will engage in transactions such as processing services for gold and platinum jewelry, consignment sales of diamond-set jewelry, and leasing properties to and from related parties [14][16][17]. - Pricing for these transactions will follow government pricing where applicable, or be based on market comparables if no government pricing exists [18][20]. Purpose and Impact of Related Transactions - The transactions with Mingpai Jewelry are expected to continue due to a strong business relationship and fair pricing, which aligns with the company's operational needs [22]. - The leasing agreements with Zhang Yiyuan and Financial Street Capital are deemed beneficial for asset utilization and operational requirements, with rental prices set at market rates [23].

Group 1 - The company held its second extraordinary general meeting of shareholders on December 5, 2025, with no resolutions being rejected [2][3] - The total number of shares with voting rights at the meeting was 746,174,300 shares after excluding shares held in the company's repurchase account [2] - The meeting was convened in accordance with the Company Law and the company's articles of association, with the chairman presiding over the meeting [3] Group 2 - The company approved several governance-related proposals, including the cancellation of the supervisory board and amendments to the articles of association [4][5] - All proposals related to the revision of governance systems and rules were passed unanimously [5][6] - The meeting was attended by all directors and supervisors, and the voting procedures were deemed valid [4][7] Group 3 - The company announced an expected related party transaction with Shengtong Intelligent Technology Co., Ltd., for a total amount not exceeding 16.5 million yuan for the year 2026 [11][12] - The transaction involves the provision of digital services and does not constitute a major asset reorganization [11] - The company had previously engaged in related transactions with Shengtong Intelligent amounting to 993.18 million yuan, which did not exceed 5% of the latest audited net assets [11][12] Group 4 - The company’s main business is non-clinical drug research services, and the collaboration with Shengtong Intelligent is expected to enhance operational efficiency and reduce costs [18] - The pricing for the services provided by Shengtong Intelligent will be based on a cost-plus model, ensuring alignment with market rates [16] - The independent directors and the board approved the related party transaction, confirming it aligns with the company's operational needs [19][20] Group 5 - The company plans to engage in daily related party transactions with Shuyitai Shen (Beijing) Biopharmaceutical Co., Ltd., which have been approved by the board [58][60] - These transactions are necessary for daily operations and are priced at market rates, ensuring no harm to the interests of the company or minority shareholders [65][66] - The company maintains its independence, with no reliance on these transactions for its main business or revenue [66] Group 6 - The company announced plans for entrusted financial management for 2026, with a maximum daily balance of 2 billion yuan for investments in low-risk financial products [69][72] - The purpose of the financial management is to enhance the efficiency of idle funds while ensuring the company's normal operations are not affected [71][78] - The board approved the financial management plan, which includes strict risk control measures [76][78] Group 7 - The company elected a new employee representative director, Li Ye, during the first meeting of the labor union committee on December 5, 2025 [79][80] - The new board will consist of 10 members, including 5 non-independent directors and 4 independent directors, complying with relevant regulations [79][80] - Li Ye has been with the company since 2007 and holds shares in the company, ensuring no conflicts of interest [80]

■ 修订后的《公司章程》全文同日披露于上海证券交易所网站（www.sse.com.cn）。 三、修订、制定公司部分治理制度的情况 为进一步规范公司运作，完善公司治理，根据《中华人民共和国公司法》《中华人民共和国证券法》等 法律、法规和规范性文件的最新规定，结合公司实际情况，拟修订、制定部分公司治理制度，具体情况 如下： ■ 修订后的制度全文同日披露于上海证券交易所网站（www.sse.com.cn）。 特此公告。 晋亿实业股份有限公司 董 事 会 二○二五年十二月四日 证券代码：601002 证券简称：晋亿实业 公告编号：2025-028 晋亿实业股份有限公司 关于召开2025年第一次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ●股东大会召开日期：2025年12月19日 ●本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票系统 一、召开会议的基本情况 (一)股东大会类型和届次 2025年第一次临时股东大会 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决 ...

Group 1 - The company held its fourth extraordinary general meeting of shareholders on December 3, 2025, with no proposals being rejected [1][5] - The meeting was attended by 1,892 shareholders and representatives, representing 1,011,622,736 shares, which is 35.37% of the total voting shares [3] - The meeting approved the appointment of Ernst & Young Hua Ming as the auditor for the 2025 financial report and internal control, with 99.78% of the votes in favor [4][7] Group 2 - The company will hold its sixth extraordinary general meeting of shareholders on December 19, 2025, with a combination of on-site and online voting [14][15] - The meeting will discuss several proposals, including the approval of a credit limit for accounts receivable factoring not exceeding RMB 6 billion for 2026 [26][27] - The company plans to use up to RMB 20 billion of idle funds for entrusted wealth management, focusing on low-risk financial products [78][80] Group 3 - The company aims to mitigate foreign exchange risks by approving a foreign exchange hedging limit of up to RMB 13 billion for 2026 [57][59] - The company will provide guarantees for its wholly-owned subsidiary, Beijing Unis Digital Technology Co., Ltd., for a bank credit limit not exceeding RMB 583.14 million [69][70] - The company has established a comprehensive internal control system to manage investment risks associated with entrusted wealth management [81][82]

Group 1 - The company will hold its first extraordinary general meeting of shareholders in 2025 on December 19, 2025 [2][5] - The meeting will be conducted using a combination of on-site and online voting methods [2][3] - The on-site meeting will take place at 14:00 on December 19, 2025, at the company's address in Zhejiang Province [2][3] Group 2 - The company plans to use up to RMB 500 million of idle funds for entrusted wealth management, which can be rolled over within this limit [21][24] - The investment period for the entrusted wealth management is from January 1, 2026, to December 31, 2026, with individual bank products not exceeding six months [21][27] - The wealth management products will be limited to low-risk, highly liquid short-term products from state-owned and listed banks [22][26] Group 3 - The company has proposed daily related transactions for 2026, which require shareholder approval [34] - The expected related transactions will not affect the company's independence, and the main business will not rely on related parties [35] - The company has established a fair pricing policy for related transactions, ensuring that they do not harm the interests of either party [41][43] Group 4 - The company has approved a comprehensive bank credit limit application of up to RMB 2.5 billion for 2026, which will be used for daily operational funding [73] - The credit limit will be valid from January 1, 2026, to December 31, 2026, and can be reused within this period [73][74] Group 5 - The company has decided to cancel its supervisory board and amend its articles of association accordingly [76] - The powers of the supervisory board will be transferred to the audit committee of the board of directors [76][77]

Core Viewpoint - Yuheng Pharmaceutical announced the investment of 210 million yuan in financial products from October 17, 2025, to December 3, 2025, utilizing idle funds [2] Group 1 - The company has recently invested 50 million yuan in the Xinyin Wealth Management's Anyingxiang Fixed Income Stable Income Closed-end Product No. 212 [2] - The investment period for the newly purchased financial product is 92 days, starting from December 3, 2025 [2] - The performance benchmark for the financial product ranges from 1.85% to 2.15% [2]

南财智讯12月3日电，紫光股份公告，公司及下属子公司拟使用不超过人民币20亿元的自有资金进行委 托理财，投资于安全性高、流动性好的短期低风险银行理财产品、无本金损失条款的结构性存款和货币 型基金。该事项已通过公司第九届董事会第十七次会议审议通过，无需提交股东会审议，资金来源合法 合规，投资额度在12个月内可循环滚动使用。 ...